Skip to content
Companies

AirNexis Therapeutics

Inhaled PDE3/4 inhibitor for COPD maintenance

  • Palo Alto, CA
  • Founded 2024
  • Biotech

Raised to date

$62M

of $200M offered across 1 Form D filing

Still open
$138M
Investors
13
Last filed
Mar 9, 2026

About

A clinical-stage biotechnology startup founded in January 2026, focused on developing and commercializing novel therapeutics for respiratory diseases like chronic obstructive pulmonary disease (COPD). The company's business model involves in-licensing late-stage clinical assets and advancing them through global development outside of Greater China. Its lead program is a dual PDE3/4 inhibitor for COPD maintenance treatment.

The company launched with a significant $200 million Series A financing and a clinical-stage asset, AN01, allowing it to bypass early discovery and focus immediately on late-stage global development. This strategy, combined with an experienced leadership team and strong investor backing, positions it to quickly address unmet needs in the large COPD market.

Funding

  • EquityFiled Mar 9, 2026Form D
    $62M/ $200M

Product

AN01 (HSK39004)

COPD Therapeutic

AN01 is an inhaled, dual-mechanism phosphodiesterase 3 and 4 (PDE3/4) inhibitor in Phase 2 development. It is intended for the maintenance treatment of COPD. The company holds exclusive global development rights outside of Greater China, having licensed the asset from Haisco Pharmaceutical Group, which previously advanced it through Phase 2 trials in China.

  • Dual mechanism of action that promotes bronchodilation to expand airways and concurrently reduces inflammatory factors.
  • Offered in multiple dosage formats, including an inhalation suspension and an inhalation powder, providing options for patient administration.
  • A clinical-stage asset with existing human safety and efficacy data from prior development in China.

Built for

Patients with chronic obstructive pulmonary disease (COPD) requiring long-term maintenance therapy to manage symptoms and reduce exacerbations.

People on file